Development of GS-441524 derivatives as potent SARS-CoV-2 Mac1 inhibitors via a direct-to-biology approach.
- DOI
- 10.1016/j.ejmech.2026.119280
- Published
- 2026 Sep 10
- Container
- European journal of medicinal chemistry
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.ejmech.2026.119280,
title = {Development of GS-441524 derivatives as potent SARS-CoV-2 Mac1 inhibitors via a direct-to-biology approach.},
author = {Peng K and Chakraborty S and Wallace SD and Noll JCG and Shang J and Lu X and Choi A and Whittaker G and Fromme JC and Lin H},
year = {2026},
journal = {European journal of medicinal chemistry},
doi = {10.1016/j.ejmech.2026.119280},
url = {https://doi.org/10.1016/j.ejmech.2026.119280}
}RIS
TY - JOUR TI - Development of GS-441524 derivatives as potent SARS-CoV-2 Mac1 inhibitors via a direct-to-biology approach. AU - Peng K AU - Chakraborty S AU - Wallace SD AU - Noll JCG AU - Shang J AU - Lu X AU - Choi A AU - Whittaker G AU - Fromme JC AU - Lin H PY - 2026 JO - European journal of medicinal chemistry DO - 10.1016/j.ejmech.2026.119280 UR - https://doi.org/10.1016/j.ejmech.2026.119280 ER -
APA
K, P., S, C., SD, W., JCG, N., J, S., X, L., A, C., G, W., JC, F., & H, L. (2026). Development of GS-441524 derivatives as potent SARS-CoV-2 Mac1 inhibitors via a direct-to-biology approach.. European journal of medicinal chemistry. https://doi.org/10.1016/j.ejmech.2026.119280
Source records
- pubmed · retrieved 2026-09-26T04:18:11.177Z